-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

226 CD20-Tcb (RG6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma: Preliminary Results from a Phase I First in Human Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Immunotherapy
Hematology Disease Topics & Pathways:
Biological, Diseases, antibodies, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Lymphoid Malignancies
Saturday, December 1, 2018: 4:45 PM
Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

Martin Hutchings, MD, PhD1*, Gloria Iacoboni, MD2*, Franck Morschhauser, MD3*, Fritz Offner, MD4, Anna Sureda, MD5*, Gilles Andre Salles, MD, PhD6, Carmelo Carlo-Stella, MD7, Joaquin Martinez Lopez, MD8*, Denise Thomas, BS9*, Peter N Morcos, PhD10*, Betsy Quackenbush, MD9*, Cristiano Ferlini, MD11*, Marina Bacac, PhD12*, Ann-Marie E. Broeske, PhD13*, Natalie Dimier, PhD14*, Tom Moore, MD11*, Martin Weisser, MD15* and Michael Dickinson, MBBS, FRACP, FRCPA16

1Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DNK
2Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
3Hôpital Claude Huriez, Université de Lille, Lille, France
4Universitair Ziekenhuis Gent, Ghent, Belgium
5Hematology Department, Institut Català d'Oncologia Hospitalet, Barcelona, Spain
6Service d'Hématologie Clinique, Hospices Civils de Lyon - Université de Lyon, Lyon, France
7Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas University, Milan, Italy
8Hospital Universitario 12 de Octubre, Madrid, Spain
9Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY
10Roche Innovation Center New York, Roche Pharma Research and Early Development Roche Innovation Center New York,, New York
11Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland
12Roche Innovation Center Zurich, Roche Glycart, Schlieren Zurich, Switzerland, Switzerland
13Roche Innovation Center Munich, Roche Pharma Research And Early Development, Penzberg, DEU
14Roche Products Ltd, Welwyn Garden City, United Kingdom
15Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany
16Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia

Despite advancements in outcomes with the introduction of anti-CD20 monoclonal antibody therapy, a substantial proportion of B-cell Non-Hodgkin’s Lymphoma (B-NHL) patients do not sustain a durable response to standard of care treatment. T-cell bispecific antibodies (TCBs) represent a new class of disease‑targeting agents shown to activate T-cells to kill cancer cells, offering this exciting mechanism of action with ‘off the shelf’ availability. CD20-TCB (RG6026) is a novel T-cell-engaging bispecific antibody whose “2:1” format possesses two CD20 binders in addition to a CD3 binder, enabling increased tumor antigen avidity, rapid T‑cell activation, and enhanced tumor cell killing. NP30179 is a multicenter phase I dose escalation trial investigating the safety, tolerability, pharmacokinetics (PK), biomarker responses, and antitumor activity (assessed by overall response rate [ORR] and complete response rate [CR] per Lugano 2014 criteria) of single agent CD20-TCB. Patients receive escalating doses of CD20-TCB as intravenous infusions with dose escalation guided by a model implementing the Bayesian continuous reassessment method with overdose control. In order to reduce the potential risk of cytokine release syndrome (CRS) induced by CD20-TCB mediated systemic T-cell activation, a single dose of 1000 mg obinutuzumab (G) pretreatment (Gpt) is administered seven days prior to start of CD20-TCB and has preclinically been shown to debulk peripheral B cells and reduce systemic cytokine release (Bacac et al. Clin Canc Res 2018).

As of July 29th 2018 a total of 64 patients (pts) with aggressive r/r B-NHL (DLBCL/PMBCL/trFL/Richter´s transformation (n=47)) and indolent r/r B-NHL (FL(n=17)) received CD20-TCB doses ranging from 5 µg to 1800 µg in a Q2W schedule. Median age was 64 years (range 28-82), 61% were male, median prior lines of therapy was 3 (range 1-10). A single DLT (myocardial infarction) was observed at 220 µg and until the maximum tested dose CD20-TCB was well tolerated. The most reported AEs were pyrexia (n=14, all Gr 1 and 2), neutropenia (all grades n=17, Gr 3 and 4 n=14) and cytokine release syndrome (CRS, n=14, all Grade 1-2 according to the criteria by Lee et al. Blood 2014). Two patients received tocilizumab for CRS management all CRS events were manageable and resolved, without leading to dose reduction or study withdrawal. No CNS toxicity was reported so far in this study. Fifty-five pts had at least one post-baseline response assessment and were eligible for efficacy analysis. Responses were observed from 15 µg onwards, and complete responses (CR) occurred from 300 µg onwards following two cycles of treatment. At doses of 300 µg or above (n=29) the ORR and CR rate by investigator assessment was 38% and 24%, respectively (FL: 3/5 pts and 2/5 pts respectively, aggressive B-NHL: 8/24 pts and 5/24 pts respectively). All CRs are sustained thus far with a median follow up 96 days (range 26-152). Responses were seen across various NHL subtypes and across prognostic factors such as prior lines of therapy, refractoriness to the most recent line of therapy, tumor burden, and IPI or FLIPI. CD20-TCB exposure and receptor occupancy increased dose-dependently across the investigated dose range; dose-escalation is continuing to optimize these factors. No anti-drug-antibodies have occurred.

CD20-TCB is a novel 2:1 format T-cell-engaging bispecific antibody which already at suboptimal doses displays promising clinical activity in heavily-pretreated B-NHL. In addition, Gpt has shown clinical proof of principle as an approach to efficiently mitigate CRS. An update on safety and efficacy as well as biomarker data will be presented.

Disclosures: Hutchings: Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche/Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Iacoboni: Celgene: Other: Travel funding; Roche: Honoraria. Morschhauser: Janssen: Other: Scientific Lectures; BMS: Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees. Sureda: Takeda: Consultancy, Honoraria, Speakers Bureau; Roche: Honoraria; Merck: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Sanofi: Honoraria. Salles: Janssen: Honoraria; Merck: Honoraria; Gilead Sciences: Honoraria; Epizyme: Honoraria; Amgen: Honoraria; Acerta: Honoraria; Abbvie: Honoraria; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Novartis: Consultancy, Honoraria; Morphosys: Honoraria; Pfizer: Honoraria; Servier: Honoraria; Takeda: Honoraria. Carlo-Stella: Rhizen Pharmaceuticals: Research Funding; Boehringer Ingelheim: Consultancy; Sanofi: Consultancy; MSD: Other: Advisory Board; Genenta Science: Other: Advisory Board; BMS: Other: Advisory Board; Amgen: Other: Advisory Board; Janssen: Other: Advisory Board; AstraZeneca: Other: Advisory Board; ADC Therapeutics: Other: Advisory Board. Martinez Lopez: Celgene: Research Funding, Speakers Bureau; BMS: Research Funding, Speakers Bureau; Jansen: Research Funding, Speakers Bureau; Novartis: Research Funding, Speakers Bureau. Thomas: Roche: Employment, Equity Ownership. Morcos: Roche: Employment, Equity Ownership. Quackenbush: Roche: Employment. Ferlini: Roche: Employment. Bacac: F. Hoffmann-La Roche Ltd.: Employment, Other: stock, Patents & Royalties. Broeske: Roche: Employment, Equity Ownership. Dimier: Roche: Employment, Equity Ownership. Moore: Roche: Employment. Weisser: Roche: Employment, Equity Ownership, Patents & Royalties. Dickinson: GSK: Consultancy.

*signifies non-member of ASH